Literature DB >> 16473356

Conducting industry-partnered trials in orthopaedic surgery.

Mohit Bhandari1, Anders Jönsson, Volker Bühren.   

Abstract

We have seen an emergence of larger scale collaborative multi-center trials in surgery. These larger trials have the advantage of increased generalisability of the results and the potential for large scale and efficient recruitment (1000 patients or more). It is estimated that the average cost of bringing a new drug to market approximates 500 million dollars. The funding limitations in most national peer-reviewed agencies provides a compelling rationale for industry co-sponsors. To limit biases associated with industry-sponsored research, researchers should develop specific protocols to ensure accurate and transparent reporting of funding sources, design and implementation of surgical trials, manuscript preparation and the criteria for authorship.

Entities:  

Mesh:

Year:  2006        PMID: 16473356     DOI: 10.1016/j.injury.2006.01.029

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  4 in total

1.  Cochrane in CORR®: Arthroplasty versus fusion in single-level cervical degenerative disc disease.

Authors:  Nathan Evaniew; Kim Madden; Mohit Bhandari
Journal:  Clin Orthop Relat Res       Date:  2014-03       Impact factor: 4.176

2.  Challenges for Large Orthopaedic Hospitals Worldwide-An ISOC Position Statement.

Authors:  Patrick S Sussmann; Beat R Simmen; Joerg Goldhahn; Thomas P Sculco
Journal:  HSS J       Date:  2009-12-11

Review 3.  RANDOMIZED CONTROLLED CLINICAL TRIALS IN ORTHOPEDICS: DIFFICULTIES AND LIMITATIONS.

Authors:  Eduardo Angeli Malavolta; Marco Kawamura Demange; Riccardo Gomes Gobbi; Marta Imamura; Felipe Fregni
Journal:  Rev Bras Ortop       Date:  2015-11-17

4.  APPLICABILITY OF RANDOMIZED TRIALS IN HAND SURGERY: SURVEY STUDY.

Authors:  Vinícius Ynoe DE Moraes; Priscila Frantz Ruff; Carlos Henrique Fernandes; João Baptista Gomes Dos Santos; João Carlos Belloti; Flávio Faloppa
Journal:  Acta Ortop Bras       Date:  2018 May-Jun       Impact factor: 0.513

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.